Tagged with IQVIA

Asia-Pacific To cater to Japan and Asia Pacific (JAPAC)’s booming biotech industry, in May 2021 IQVIA expanded its ‘IQVIA Biotech’ brand into the region. Looking ahead to 2022, IQVIA Biotech JAPAC has identified six key trends for emerging biotechs to watch. For a full interview with Senthil Sockalingam, head of IQVIA…

Denmark Kenneth Mikkelsen & Jeroen ter Borg describe the work of IQVIA – the world’s biggest CRO and life science data services provider – in Denmark, which has served as a testbed for the rollout of the firm’s healthcare business. Mikkelsen and ter Borg also highlight some of the key market…

Asia-Pacific Asia has experienced a biotech boom in the past five years. In 2020, almost 50 percent of the region’s clinical trials were led by biotechs and by 2025, biotech-led clinical trials will far exceed those led by Big Pharma, according to IQVIA. However, the region’s biotechs face a myriad of…

Singapore IQVIA Biotech JAPAC’s Dr Senthil Sockalingam outlines the evolving needs of the flood of early-stage drug discovery ventures in Asia, how biotechs in the region differ from their counterparts in the US and Europe, and the most important digitalisation trends to emerge from the COVID-19 pandemic.   Almost 50 percent…

Long Read Squirreled away in the lowlands of North West Europe and somewhat dwarfed by the mighty neighbouring pharmaceutical powerhouses of Germany and France, one could easily be forgiven for overlooking Belgium’s zesty life science ecosystem. At first glance, the numbers certainly appear more steady than thrilling: a EUR 5.4 billion domestic…

Brazil Panorama Faramceutico’s editorial team look at how the ongoing COVID-19 pandemic stands to affect Brazil’s over the counter (OTC) market segment during and after the COVID-19 pandemic.*   The OTC segment represents more than 40 percent of the self-service market in pharmacies. As it covers items with exclusive sale in…

Romania According to a 2015 United Nations International Migration Report, since Romania joined the European Union in 2007, around 3.4 million Romanians have left the country in search of a better quality of life and economic opportunity.   In 2019, the number of babies born in Romania was approximately 182,000, making…

Mexico Mario Muniz, SVP and GM of IQVIA North LATAM, shares his motivations for joining IQVIA after nearly two decades with pharma and medtech companies, the huge potential of the North LATAM region as well as the important value that IQVIA can provide during this tumultuous period within the Mexican public…

Romania Sorin Petcu of IQVIA Romania explains how financing, a lack of medical professionals, and an array of unmet needs are the major trends currently shaping Romanian healthcare. Petcu highlights IQVIA’s recent launching of patient support programs, the success of Oncology Dynamics, and how private healthcare providers can offer support to…

Belgium Despite a population size of only 11.4 million (ninth in Europe), Belgium is the continent’s fifth biggest spender on R&D, behind only Germany, Switzerland, the UK, and France according to the latest EFPIA data. The country has a long-established tradition of excellence in clinical trials and AmCham Belgium estimates that…

Morocco Ensuring the country’s “sanitary sovereignty” has long been a key policy for Morocco and its government. In order to encourage the local production of drugs, Law 17-04 was promulgated in 2006 requiring pharma companies to operate a manufacturing, control and storage site in order to apply for marketing authorization.  …

Belgium Frank Swaelens, general manager of IQVIA in Belgium and Luxembourg, offers insights into the healthcare and life science ecosystem of Belgium and highlights the opportunities that exist for the country in innovation and digitalization. Swaelens goes on to describe the collaborative role that IQVIA can play as a human data…